Evaluation of the Efficacy of Potassium Iodide Preparation for Radioactive Iodine Therapy in Graves’ Disease: A Retrospective Chart Review

Seigo Tachibana, Hiroyuki Yamashita, Toshihiko Yanase

Abstract


Background: Pretreatment by antithyroid drugs (ATDs) before radioactive iodine therapy (RAIT) for Graves’ disease (GD) is often performed to avoid aggravation of thyroid function including thyroid storm. However, in patients suffering from adverse effects of ATDs, potassium iodide (KI) is often selected to treat hyperthyroidism before RAIT in Japan. The aim of this study was to evaluate the efficacy of KI preparation for RAIT in GD and whether a short-term discontinuation of KI before RAIT is a safe and useful method in GD patients showing adverse effects from ATDs.

Methods: This is a retrospective chart review. The 24 patients enrolled in this study were divided into two groups. Patients who had large goiter and/or underwent previous RAIT were excluded. Before RAIT, 11 patients were administered KI and were referred to as the KI group. The remaining 13 patients were administered methimazole (MMI) and referred to as the MMI group. Between these two groups, the following factors were compared; radioactive iodine uptake (RAIU) before RAIT, thyroid gland weight, dose of administered 131-I, dose of 131-I based on thyroid gland weight, free thyroxine (FT4) at RAIT, difference in FT4 between before and 4 days after discontinuation of drugs, and thyroid function and thyroid gland weight 1 year after RAIT.

Results: RAIU before RAIT (P = 0.0018), dose of 131-I (P = 0.0037), FT4 at RAIT (P = 0.0034), and thyroid gland weight 1 year after RAIT (P = 0.0065) showed significant differences. Thyroid gland weight, dose of 131-I based on thyroid gland weight, difference in FT4 between before drug discontinuation and at RAIT, and thyroid function at 1 year after RAIT did not show any significant differences.

Conclusion: These results suggest that most patients without large goiter and/or highly aggressive disease may be safely and efficiently treated with RAIT and KI pretreatment until 4 days before therapy.




J Endocrinol Metab. 2017;7(1):25-30
doi: https://doi.org/10.14740/jem394w

 


Keywords


Graves’ disease; Radioactive iodine therapy; Potassium iodide; Antithyroid drug

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!